Eupraxia Pharmaceuticals Inc. Common Stock (EPRX) Stock
Fundamentals
Technicals
Analyst Ratings
Financials
Performance
No data available
Debt & Balance Sheet
No data available
Revenue to Profit
No data available
Earnings
No data available
% positive news of 1 articles
published over the past 14 days
About Eupraxia Pharmaceuticals Inc. Common Stock
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with unmet medical needs. Currently, the company has two distinct clinical development programs, one targeting EoE and the second targeting chronic Osteoarthritis pain in the knee and has completed a Phase 2b clinical trial with EP-104IAR in knee OA.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. James A. Helliwell FRCPC, M.D. | CEO & Director | 1974 |
| Mr. Alexander John Rothwell Eng., M.B.A. | Chief Financial Officer | 1969 |
| Mr. Paul Anthony Brennan B.Sc., M.Sc. | Chief Corporate Development Officer | — |
| Ms. Wajida Leclerc B.A., CCP, CHRP | Executive Vice President Corporate Services & People | 1960 |
| Mr. Alex Therien | Executive VP of R&D | — |
| Dr. Jeymi Tambiah M.S. | Chief Medical Officer | — |
| Dr. Jeffrey Millard Ph.d. | Executive Vice President of Technical Operations | 1976 |
Fundamentals
Valuation
Earnings Per Share
Income Statement
Dividend
Solvency
Technicals
What the experts say
1 Wall Street Analyst Ratings
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +26.3 |




